Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: 'Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases' by Giollo et al.
Kimme L HyrichMilena GianfrancescoPedro M MachadoJinoos YazdanyPhilip C RobinsonPublished in: Annals of the rheumatic diseases (2020)
Keyphrases
- disease activity
- rheumatoid arthritis
- coronavirus disease
- sars cov
- systemic lupus erythematosus
- rheumatoid arthritis patients
- juvenile idiopathic arthritis
- ankylosing spondylitis
- emergency department
- respiratory syndrome coronavirus
- primary care
- big data
- stem cells
- machine learning
- mesenchymal stem cells
- bone marrow
- cell therapy
- artificial intelligence
- deep learning